The role of organic transporters in pharmacokinetics and nephrotoxicity of newer antiviral therapies for HIV and Hepatitis C

Current Drug Metabolism

Volumn 16, Issue 4, 2015, Pages 322-331

  Mitema, Donald ^a   Atta, Mohamed G ^b  

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral therapy; HCV; HIV; renal

Indexed keywords

ANTIRETROVIRUS AGENT; COBICISTAT; DASABUVIR; DOLUTEGRAVIR; ELVITEGRAVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RILPIVIRINE; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; CARRIER PROTEIN;

ANTIVIRAL THERAPY; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIALYSIS; DIRECT ACTING ANTIVIRAL THERAPY; DRUG RESPONSE; ETHNICITY; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; NEPHROTOXICITY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STAGING; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; HIV INFECTIONS; METABOLISM;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; MEMBRANE TRANSPORT PROTEINS;

EID: 84942098107     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920021604150902181109     Document Type: Review

References (54)

1. May, M.T.; Gompels, M.; Delpech, V.; Porter, K.; Orkin, C.; Kegg, S.; Hay, P.; Johnson, M.; Palfreeman, A.; Gilson, R.; Chadwick, D.; Martin, F.; Hill, T.; Walsh, J.; Post, F.; Fisher, M.; Ainsworth, J.; Jose, S.; Leen, C.; Nelson, M.; Anderson, J.; Sabin, C. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. Aids, 2014, 28(8), 1193.
2. Lodwick, R.K.; Sabin, C.A.; Porter, K.; Ledergerber, B.; van Sighem, A.; Cozzi-Lepri, A.; Khaykin, P.; Mocroft, A.; Jacobson, L.; De Wit, S.; Obel, N.; Castagna, A.; Wasmuth, J.C.; Gill, J.; Klein, M.B.; Gange, S.; Riera, M; Mussini, C.; Gutierrez, F.; Touloumi, G.; Carrieri, P.; Guest, J.L.; Brockmeyer, N.H.; Phillips, AN. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet, 2010, 376(9738), 340.
3. Available from: AASLD/IDSA/IAS-USA. Recommendations for testing m, and treating hepatitis C. http://www.hcvguidelines.org. Accessed on April 24, 2014.
4. Liang, T.J.; Rehermann, B.; Seeff, L.B.; Hoofnagle, J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med., 2000, 132(4), 296.
5. Yano, M.; Kumada, H.; Kage, M.; Ikeda, K.; Shimamatsu, K.; Inoue, O.; Hashimoto, E.; Lefkowitch, J.H.; Ludwig, J.; Okuda, K. The long-term pathological evolution of chronic hepatitis C. Hepatology, 1996, 23(6), 1334.
6. Niederau, C.; Lange, S.; Heintges, T.; Erhardt, A.; Buschkamp, M.; Hurter, D.; Nawrocki, M.; Kruska, L.; Hensel, F.; Petry, W.; Haussinger, D. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology, 1998, 28(6), 1687.
7. LaFleur, J.; Hoop, R.; Morgan, T.; DuVall, S.L.; Pandya, P.; Korner, E.; Knippenberg, K.; Hayden, C.; Nelson, R.E. High rates of early treatment discontinuation in hepatitis C-infected US veterans. BMC Res. Notes, 2014, 7, 266.
8. Larrey, D.; Ripault, M.P.; Pageaux, G.P. Patient adherence issues in the treatment of hepatitis C. Patient Prefer Adherence, 2014, 8, 763.
9. Mathes, T.; Antoine, S.L.; Pieper, D. Factors influencing adherence in Hepatitis-C infected patients: a systematic review. BMC Infect. Dis., 2014, 14, 203.
10. Schmidt, W.N.; Nelson, D.R.; Pawlotsky, J.M.; Sherman, K.E.; Thomas, D.L.; Chung, R.T. Direct-acting antiviral agents and the path to interferon independence. Clin. Gastroenterol. Hepatol., 2014, 12(5), 728.
11. Jacobson, I.M.; Dore, G.J.; Foster, G.R.; Fried, M.W.; Radu, M.; Rafalsky, V.V.; Moroz, L.; Craxi, A.; Peeters, M.; Lenz, O.; Ouwerkerk-Mahadevan, S.; De La Rosa, G.; Kalmeijer, R.; Scott, J.; Sinha, R.; Beumont-Mauviel, M. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet, 2014, 384(9941), 403.
12. Kowdley, K.V.; Lawitz, E.; Crespo, I.; Hassanein, T.; Davis, M.N.; DeMicco, M.; Bernstein, D.E.; Afdhal, N.; Vierling, J.M.; Gordon, S.C.; Anderson, J.K.; Hyland, R.H.; Dvory-Sobol, H.; An, D.; Hindes, R.G.; Albanis, E.; Symonds, W.T.; Berrey, M.M.; Nelson, D.R.; Jacobson, I.M. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet, 2013, 381(9883), 2100.
13. Lawitz, E.; Mangia, A.; Wyles, D.; Rodriguez-Torres, M.; Hassanein, T.; Gordon, S.C.; Schultz, M.; Davis, M.N.; Kayali, Z.; Reddy, K.R.; Jacobson, I.M.; Kowdley, K.V.; Nyberg, L.; Subramanian, G.M.; Hyland, R.H.; Arterburn, S.; Jiang, D.; McNally, J.; Brainard, D.; Symonds, W.T.; McHutchison, J.G.; Sheikh, A.M.; Younossi, Z.; Gane, EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med., 2013, 368(20), 1878.
14. Manns, M.; Pol, S.; Jacobson, I.M.; Marcellin, P.; Gordon, S.C.; Peng, C.Y.; Chang, T.T.; Everson, G.T.; Heo, J.; Gerken, G.; Yoffe, B.; Towner, W.J.; Bourliere, M.; Metivier, S.; Chu, C.J.; Sievert, W.; Bronowicki, J.P.; Thabut, D.; Lee, Y.J.; Kao, J.H.; McPhee, F.; Kopit, J.; Mendez, P.; Linaberry, M.; Hughes, E.; Noviello, S. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet, 2014, 384(9954), 1597.
15. Lawitz, E.; Sulkowski, M.S.; Ghalib, R.; Rodriguez-Torres, M.; Younossi, Z.M.; Corregidor, A.; DeJesus, E.; Pearlman, B.; Rabinovitz, M.; Gitlin, N.; Lim, J.K.; Pockros, P.J.; Scott, J.D.; Fevery, B.; Lambrecht, T.; Ouwerkerk-Mahadevan, S.; Callewaert, K.; Symonds, W.T.; Picchio, G.; Lindsay, K.L.; Beumont, M.; Jacobson, I.M. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet, 2014, 384(9956), 1756.
16. Edwards, I.R.; Aronson, J.K. Adverse drug reactions: definitions, diagnosis, and management. Lancet, 2000, 356(9237), 1255.
17. Choudhury, D.; Ahmed, Z. Drug-associated renal dysfunction and injury. Nat. Clin. Pract. Nephrol., 2006, 2(2), 80.
18. Lepist, E.I.; Zhang, X.; Hao, J.; Huang, J.; Kosaka, A.; Birkus, G.; Murray, B.P.; Bannister, R.; Cihlar, T.; Huang, Y.; Ray, A.S. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int., 2014, 86(2), 350.
19. Sekine, T.; Miyazaki, H.; Endou, H. Molecular physiology of renal organic anion transporters. Am J Physiol Renal Physiol., 2006, 290(2), F251.
20. van de Water, F.M.; Masereeuw, R.; Russel, F.G. Function and regulation of multidrug resistance proteins (MRPs) in the renal elimination of organic anions. Drug Metab. Rev., 2005, 37(3), 443.
21. Yu, X.Q.; Xue, C.C.; Wang, G.; Zhou, SF. Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs. Curr. Drug Metab., 2007, 8(8), 787.
22. Pelis, R.M.; Wright, S.H. Renal transport of organic anions and cations. Compr. Physiol., 2011, 1(4), 1795.
23. Gupta, S.K. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS, 2008, 22(2), 99.
24. Herlitz, L.C.; Mohan, S.; Stokes, M.B.; Radhakrishnan, J.; D'Agati, V.D.; Markowitz, G.S. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int., 78(11), 1171.
25. Zaidan, M.; Lescure, F.X.; Brocheriou, I.; Dettwiler, S.; Guiard- Schmid, J.B.; Pacanowski, J.; Rondeau, E.; Pialoux, G.; Girard, P.M.; Ronco, P.; Plaisier, E. Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study. Clin. J. Am. Soc. Nephrol., 2013, 8(6), 930.
26. Lucas, G.M.; Ross, M.J.; Stock, P.G.; Shlipak, M.G.; Wyatt, C.M.; Gupta, S.K.; Atta, M.G.; Wools-Kaloustian, K.K.; Pham, P.A.; Bruggeman, L.A.; Lennox, J.L.; Ray, P.E.; Kalayjian, R.C. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis., 2014, 59(9), e96.
27. Edurant(R) [package insert]. Janssen Therapeutics Titusville NhwecspEE-PpAO.
28. Garvey, L.; Winston, A. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin. Investig. Drugs, 2009, 18(7), 1035.
29. Weiss, J.; Haefeli, W.E. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int. J. Antimicrob. Agents, 2013, 41(5), 484.
30. Cohen, C.J.; Molina, J.M.; Cassetti, I.; Chetchotisakd, P.; Lazzarin, A.; Orkin, C.; Rhame, F.; Stellbrink, H.J.; Li, T.; Crauwels, H.; Rimsky, L.; Vanveggel, S.; Williams, P.; Boven, K. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. Aids, 2013, 27(6), 939.
31. Cohen, C.J.; Andrade-Villanueva, J.; Clotet, B.; Fourie, J.; Johnson, M.A.; Ruxrungtham, K.; Wu, H.; Zorrilla, C.; Crauwels, H.; Rimsky, L.T.; Vanveggel, S.; Boven, K. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet, 2011, 378(9787), 229.
32. Georgescu, V.; Le Bozec, P. [Pruritus without skin lesions]. Ann. Dermatol. Venereol., 1999, 126(8-9), 629.
33. Norman, S.P.; Kommareddi, M.; Kaul, D.R. Update on kidney transplantation in HIV-infected recipients. AIDS Rev., 2012, 14(3), 195.
34. Waheed, S.; Sakr, A.; Chheda, N.D.; Lucas, G, M.; Estrella, M.; Fine, D.M.; Atta, M.G. Outcomes of Renal Transplantation in HIV- 1 Associated Nephropathy. PLoS One, 2015, 10(6), e0129702.
35. Vassallo, M.; Dunais, B.; Naqvi, A.; Garaffo, R.; Durant, J. Raltegravir-induced nephrolithiasis: a case report. Aids, 2012, 26(10), 1323.
36. Dori, L.; Buonomini, AR; Viscione, M.; Sarmati, L.; Andreoni, M. A case of rhabdomiolysis associated with raltegravir use. Aids, 2010, 24(3), 473.
37. Castellino, S.; Moss, L.; Wagner, D.; Borland, J.; Song, I.; Chen, S.; Lou, Y.; Min, S.S.; Goljer, I.; Culp, A.; Piscitelli, S.C.; Savina, PM. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob. Agents Chemother., 2013, 57(8), 3536.
38. Tivicay, R. ViiV Healthcare RTP, NC 2014. https://www. viivhealthcare.com/media/58599/us-tivicay.pdf Accessed October 1, 2014.
39. Cottrell, M.L.; Hadzic, T.; Kashuba, A.D. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin. Pharmacokinet., 2013, 52(11), 981.
40. Koteff, J.; Borland, J.; Chen, S.; Song, I.; Peppercorn, A.; Koshiba, T.; Cannon, C.; Muster, H.; Piscitelli, S.C. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br. J. Clin. Pharmacol., 2013, 75(4), 990.
41. Weller, S.; Borland, J.; Chen, S.; Johnson, M.; Savina, P.; Wynne, B.; Wajima, T.; Peppercorn, A.F.; Piscitelli, S.C. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur. J. Clin. Pharmacol., 2014, 70(1), 29.
42. Ramanathan, S.; Mathias, A.A.; German, P.; Kearney, B.P. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin. Pharmacokinet., 2011, 50(4), 229.
43. Deeks, E.D. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs, 2014, 74(2), 195.
44. German, P.; Liu, H, C.; Szwarcberg, J.; Hepner, M.; Andrews, J.; Kearney, B.P.; Mathias, A. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J. Acquir. Immune Defic. Syndr., 2012, 61(1), 32.
45. Arya, V.; Florian, J.; Marcus, K.A.; Reynolds, K.S.; Lewis, L.L.; Sherwat, A.I. Does an increase in serum creatinine always reflect renal injury? The case of Stribild(R). J. Clin. Pharmacol., 2013.
46. Maggi, P.; Montinaro, V.; Rusconi, S.; Di Biagio, A.; Bellagamba, R.; Bonfanti, P.; Calza, L.; Corsi, P.; Montella, F.; Mussini, C. The problem of renal function monitoring in patients treated with the novel antiretroviral drugs. HIV Clin. Trials, 2014, 15(3), 87.
47. Stray, K.M.; Bam, R.A.; Birkus, G.; Hao, J.; Lepist, E.I.; Yant, S.R.; Ray, A.S.; Cihlar, T. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Antimicrob. Agents Chemother., 2013, 57(10), 4982.
48. Stribild, R. Gilead Sciences I, Foster City, CA. 2012. http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/stribild/st ribild-pi.ashx Accessed October 1, 2014.
49. Olysio, R. Janssen Therapeutics TNhwafgddlslpAO.
50. Hayashi, N.; Izumi, N.; Kumada, H.; Okanoue, T.; Tsubouchi, H.; Yatsuhashi, H.; Kato, M.; Ki, R.; Komada, Y.; Seto, C.; Goto, S. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J. Hepatol., 2014, 61(2), 219.
51. Sovaldi, R. Gilead Sciences I, Foster City, CA. 2013 https://www.gilead.com/~/media/Files/pdfs/medicines/liverdisease/ sovaldi/sovaldi-pi.pdf Accessed October 1, 2014.
52. Harvoni, R. Gilead Sciences I, Foster City, CA. 2012. http:// www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/ harvoni-pi.pdf Accessed May 14, 2015.
53. Gritsenko, D.; Hughes, G. Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. P T, 2015, 40(4), 256.
54. Viekira Pak, R. AbbVie Inc. NC, IL. http://www.accessdata. fda.gov/drugsatfda-docs/label/2014/206619lbl.pdf Accessed via FDA website May 19, 2015.